Nuvation Bio's Safusidenib Posts Durable Responses in IDH1 Glioma

Nuvation Bio opened the week with fresh evidence that its brain-cancer candidate can deliver durable responses. The company (NYSE: NUVB) is a commercial-stage oncology developer, and safusidenib, an oral IDH1 inhibitor, is one of its key pipeline assets in glioma.

On July 20, 2026, Nuvation announced positive updated Phase 2 data from the J201 study of safusidenib in patients with grade 2 IDH1-mutant glioma, and said it would expand the program with two new studies. The centrally assessed confirmed overall response rate was 51.9% under RANO low-grade glioma criteria, median progression-free survival had not been reached, and the 36-month progression-free survival rate was 79.1%. No new safety signals were identified. The company plans a Phase 3 study, G307, enrolling roughly 140 patients with newly diagnosed grade 2 IDH1-mutant glioma who have not yet received chemotherapy or radiation, at sites outside the United States.

Phase 2 responses in a defined subgroup may not translate into a successful, larger placebo-controlled trial. This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.